Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 7;24(1):96.
doi: 10.1186/s13063-023-07074-w.

Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs

Hansel E Tookes  1 , Asa Oxner  2 , David P Serota  3 , Elizabeth Alonso  4 , Lisa R Metsch  5 , Daniel J Feaster  6 , Jessica Ucha  4 , Edward Suarez Jr  7 , David W Forrest  8 , Kathryn McCollister  4 , Allan Rodriguez  3 , Michael A Kolber  3 , Teresa A Chueng  3 , Sheryl Zayas  9 , Bernice McCoy  2 , Kyle Sutherland  3 , Chetwyn Archer  3 , Tyler S Bartholomew  4
Affiliations

Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs

Hansel E Tookes et al. Trials. .

Abstract

Background: The resurgence of HIV outbreaks and rising prevalence among people who inject drugs (PWID) remain exigent obstacles to Ending the HIV Epidemic in the USA. Adapting a low threshold, comprehensive treatment model for PWID with HIV can leverage syringe services programs (SSPs) to increase availability and accessibility of antiretrovirals (ART), medications for opioid use disorder (MOUD), and hepatitis C cure. We developed Tele-Harm Reduction, a telehealth-enhanced, harm reduction intervention delivered within an SSP venue.

Methods: The T-SHARP trial is an open-label, multi-site, randomized controlled superiority trial with two parallel treatment arms. Participants (n=240) recruited from SSPs in Miami, Ft. Lauderdale, and Tampa, Florida, who are PWID with uncontrolled HIV (i.e., HIV RNA>200) will be randomized to Tele-Harm Reduction or off-site linkage to HIV care. The primary objective is to compare the efficacy of Tele-Harm Reduction for initiation of ART at SSPs vs. off-site linkage to an HIV clinic with respect to viral suppression across follow-up (suppression at 3, 6, and 12 months post randomization). Participants with HIV RNA<200 copies/ml will be considered virally suppressed. The primary trial outcome is time-averaged HIV viral suppression (HIV RNA <200 copies/ml) over 3-, 6-, and 12-month follow-up. Secondary outcomes include initiation of MOUD measured by urine drug screen and HCV cure, defined as achieving 12-week sustained virologic response (negative HCV RNA at 12 weeks post treatment completion). A cost-effectiveness analysis will be performed.

Discussion: The T-SHARP Trial will be the first to our knowledge to test the efficacy of an innovative telehealth intervention with PWID with uncontrolled HIV delivered via an SSP to support HIV viral suppression. Tele-Harm Reduction is further facilitated by a peer to support adherence and bridge the digital divide. This innovative, flipped healthcare model sets aside the traditional healthcare system, reduces multi-level barriers to care, and meets PWID where they are. The T-SHARP trial is a pragmatic clinical trial that seeks to transform the way that PWID access HIV care and improve HIV clinical outcomes.

Trial registration: ClinicalTrials.gov NCT05208697. Trial registry name: Tele-Harm Reduction. Registration date: January 26, 2022.

Keywords: HIV; Harm reduction; People who inject drugs; Syringe services program; Telehealth.

PubMed Disclaimer

Conflict of interest statement

HET and TSB report research grants from Gilead Sciences and ViiV. SZ is on the speaker’s bureau for Gilead Sciences. AO, DPS, EA, LRM, DJF, JU, ES, DWF, KM, AR, MAK, TAC, KS, SZ, BM, and CA declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
RCT study flow
See this image and copyright information in PMC

References

    1. Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs' role in ending the HIV epidemic in the U.S.: why we cannot do it without them. Am J Prev Med. 2021;61(5 Suppl 1):S118–SS29. - PMC - PubMed
    1. Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596. - PMC - PubMed
    1. Lyss SB, Buchacz K, McClung RP, Asher A, Oster AM. Responding to outbreaks of human immunodeficiency virus among persons who inject drugs-United States, 2016-2019: Perspectives on Recent Experience and Lessons Learned. J Infect Dis. 2020;222(Suppl 5):S239–SS49. - PubMed
    1. Williams LD, Ibragimov U, Tempalski B, Stall R, Satcher Johnson A, Wang G, et al. Trends over time in HIV prevalence among people who inject drugs in 89 large US metropolitan statistical areas, 1992-2013. Ann Epidemiol. 2020;45:12–23. - PMC - PubMed
    1. Tookes H, Bartholomew TS, Geary S, Matthias J, Poschman K, Blackmore C, et al. Rapid identification and investigation of an HIV risk network among people who inject drugs -Miami, FL, 2018. AIDS Behav. 2020;24(1):246–256. - PMC - PubMed

Publication types

MeSH terms

Associated data